Development of monoclonal antibodies to prevent and treat infections from Flaviviruses

Overview

Funding for the development of monoclonal antibodies to prevent and treat infections caused by specific Flaviviruses, targeting researchers, SMEs, and consortia advancing clinical-stage candidates toward regulatory approval.

Who Can Apply

Legal entities established in eligible EU Member States, Horizon Europe Associated Countries, the United Kingdom, Switzerland, and the United States. Participation of SMEs, start-ups, and third-country partners from endemic regions is encouraged.

Funding Details

Maximum grant amount: 11,000,000 EUR per project.

What Is Funded

Development of prophylactic and therapeutic monoclonal antibodies (e.g., B-cell derived, hybridoma derived, or nanobodies) targeting one of the following Flaviviruses: Dengue Virus, Tick-borne Encephalitis Virus, Japanese Encephalitis Virus, West Nile Fever Virus, Yellow Fever Virus, or Zika Virus. Activities include:

• Final in-vitro characterization of antibody candidates.
• In-vivo testing in animal models (including humanised immune system models or non-human primates if required).
• Evaluation of Antibody-Dependent Enhancement (ADE) risk.
• GMP-compliant production of antibody batches.
• First-in-human clinical safety studies with a clear regulatory pathway.

Technology / Maturity Requirements

Projects must target Technology Readiness Levels (TRL) 7–9, focusing on late-stage development and clinical validation.

Key Dates

• Open date: 2027-02-09
• Deadline: 2027-04-12T22:00:00Z

Application Process (High-Level)

Single-stage application process via the Funding & Tenders Portal. Proposals must include a dedicated annex for clinical studies using the provided template.

Post-Award Obligations

• Timely engagement with regulatory bodies.
• Compliance with Good Manufacturing Practices (GMP) for antibody production.
• Reporting and dissemination of results, including clinical study details.
• The granting authority may object to transfers of ownership or exclusive licensing of results for up to four years post-project.

Geographic Scope & Language

Eligible countries: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Norway, Iceland, United Kingdom, Switzerland, and the United States. Application language: English.

Notes

• Proposals must target a single Flavivirus.
• Participation of third countries with endemic virus presence is encouraged.
• Projects must leverage existing research infrastructures (e.g., ISIDORe).
• Evaluation prioritizes a balanced portfolio across targeted Flaviviruses.